Investment In China's Biopharma R&D Shrinking?
This article was originally published in PharmAsia News
Executive Summary
Despite steady growth in biopharmaceutical earnings and profits, the field's R&D has been witnessing reduced investment worldwide including in China, says a report by Ernest & Young, citing small firms' financing difficulties